DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Respiratory Distress Syndrome, Newborn

Intervention: Betamethasone (Drug)

Phase: Phase 2/Phase 3

Status: Terminated

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Lucky Jain, M.D., Principal Investigator, Affiliation: Emory University Department of Pediatrics, Division of Neonatology


This is a randomized, multicenter, double blind, placebo controlled trial of betamethasone versus a placebo given prior to the mothers at term and near term gestation (>34 and <40 weeks of gestation) who are scheduled to undergo a planned Cesarean section. The study design is to determine the efficacy and safety of betamethasone in the prevention of breathing problems commonly seen in this population. In infants born by elective Cesarean section, it is hypothesized that antenatal betamethasone treatment will reduce the risk of neonatal intensive care unit (NICU) admission from 11% to 8% and/or oxygen therapy +/- positive pressure ventilation (PPV) for >30 minutes from 4. 5% to 2. 5%.

Clinical Details

Official title: Randomized Controlled Trial of Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: The primary outcome to be studied is the need for NICU admission and/or oxygen therapy or PPV for >30 minutes.

Detailed description: The purpose of this pilot study is to determine if antepartum betamethasone given to mothers undergoing elective cesarean section (ECS) delivery at term or near term gestation (>34 and < 40 weeks of gestation) is safe and feasible in reducing neonatal respiratory morbidity and the related admissions to neonatal intensive care units (NICU). The data from this pilot study will be used to support a NIH application for a multicenter randomized trial to determine, if compared to placebo treatment, antenatal betamethasone initiated 2-7 days prior to an ECS results in decreased occurrence of respiratory morbidity and NICU admissions in the newborn. The multicenter protocol was recently reviewed by the NICHD network for clinical trial. The reviewers were enthusiastic about the scientific merit and public health importance of the study but asked for a pilot study to determine feasibility before launching the national trial. Given the rise in the rate of CS deliveries, we project substantial health cost savings from this preventive strategy if it were found to be successful in reducing neonatal morbidity.


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Pregnant women >/= 34 weeks gestation scheduled to undergo operative delivery within

48-72 hours after study enrollment Exclusion Criteria:

- Known contraindication to the use of betamethasone in the mother

- Known lethal or non-lethal congenital anomaly diagnosed antenatally

- Spontaneous labor

- Premature rupture of membranes

Locations and Contacts

Emory University affiliated newborn intensive care units, Atlanta, Georgia 30322, United States
Additional Information

Starting date: August 2005
Last updated: November 25, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017